← Back to Search

Cancer Screening for Lung Cancer

N/A

Waitlist Available

Led By Christine D Berg

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

Awards & highlights

Study Summary

This trial is testing whether screening for various types of cancer can reduce deaths from those cancers.

Who is the study for?

This trial is for older individuals who may be at risk of lung cancer. Participants will undergo screening methods to detect any signs of cancer early on, which could lead to better treatment outcomes.Check my eligibility

What is being tested?

The study is testing the effectiveness of a screening questionnaire and X-ray imaging in identifying lung cancer in its early stages, with the goal of reducing mortality from this disease.See study design

What are the potential side effects?

There are generally minimal side effects associated with completing a screening questionnaire and undergoing X-ray imaging. However, there might be some discomfort or anxiety related to the procedures.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years.

This trial's timeline: 3 weeks for screening, Varies for treatment, and events through 13 years of follow-up or through december 31, 2009; median follow-up 11.9 years. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Lung Cancer Death Rates

Lung Cancer Deaths

Secondary outcome measures

Complications of Diagnostic Evaluation Following a Positive Screening Test

Death Rates From All Causes

Deaths From All Causes

+6 more

Trial Design

2Treatment groups

Active Control

Group I: Lung ScreeningActive Control2 Interventions

Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as "smokers" undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial.

Group II: ControlActive Control1 Intervention

Participants receive standard medical care. Participants complete a DHQ at baseline.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor

13,657 Previous Clinical Trials

40,778,766 Total Patients Enrolled

Christine D BergPrincipal InvestigatorNational Cancer Institute (NCI)

3 Previous Clinical Trials

309,801 Total Patients Enrolled

Media Library

X-Ray Imaging Clinical Trial Eligibility Overview. Trial Name: NCT01696968 — N/A

Lung Cancer Research Study Groups: Lung Screening, Control

Lung Cancer Clinical Trial 2023: X-Ray Imaging Highlights & Side Effects. Trial Name: NCT01696968 — N/A

X-Ray Imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT01696968 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What objectives is this medical experiment attempting to attain?

"The primary objective of this clinical trial is to gauge the number of lung cancer deaths over a 13 year period, with an average follow-up time frame of 11.9 years. Secondary outcomes include Complications arising from Diagnostic Evaluation Following Positive Screening Test, T1 CXR Screenings Results, and Lung Cancer Incidence confirmed through medical records abstraction."

Answered by AI

Who is eligible to participate in this experiment?

"To meet the eligibility requirements for this medical trial, applicants must be aged between 55 and 74, as well as having a diagnosis of lung carcinoma. A total of 154901 participants are being enrolled in this study."

Answered by AI

Are there any vacancies for this clinical experiment?

"Clinicaltrials.gov data reveals that this medical investigation is not currently enrolling patients, despite being initially posted in November 1993 and having its details edited on June 30th 2022. Yet, 1507 other studies are actively seeking participants at present time."

Answered by AI

Can seniors aged 60 or more participate in this experiment?

"This trial is open to those aged between 55 and 74. For younger patients, there are 36 separate trials available while 1502 exist for the elderly population."

Answered by AI

Recent research and studies

Clinical NutritionJournal

Vitamin K Intake and Breast Cancer Incidence and Death: Results from a Prospective Cohort Study

Wang, Kang, Qianxue Wu, Zhuyue Li, Michael K. Reger, Yongfu Xiong, Guochao Zhong, Qing Li, et al.. 2021. “Vitamin K Intake and Breast Cancer Incidence and Death: Results from a Prospective Cohort Study”. Clinical Nutrition. Elsevier BV. doi:10.1016/j.clnu.2020.11.009.

Clinical Breast CancerJournal

Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results from a Prospective Cohort Study

Jiang, Yi, QinLi Xie, and Rong Chen. 2022. “Breast Cancer Incidence and Mortality in Relation to Hormone Replacement Therapy Use Among Postmenopausal Women: Results from a Prospective Cohort Study”. Clinical Breast Cancer. Elsevier BV. doi:10.1016/j.clbc.2021.06.010.

BMC MedicineJournal

Associations of Genetic Risk, BMI Trajectories, and the Risk of Non-small Cell Lung Cancer: A Population-based Cohort Study

You, Dongfang, Danhua Wang, Yaqian Wu, Xin Chen, Fang Shao, Yongyue Wei, Ruyang Zhang, et al.. 2022. “Associations of Genetic Risk, BMI Trajectories, and the Risk of Non-small Cell Lung Cancer: A Population-based Cohort Study”. BMC Medicine. Springer Science and Business Media LLC. doi:10.1186/s12916-022-02400-6.

clinicaltrials.govStudy